Relationship between magnesium and lipids in patients with diabetes mellitus by Jansen van Vuuren, J.M. et al.
Relationship between magnesium and lipids in patients with diabetes mellitus
JM Jansen van Vuurena* , S Pillayb and CJ Jansen van Vuurenc
aNorthdale Hospital, Pietermaritzburg, South Africa
bEdendale Hospital, Pietermaritzburg, South Africa
cuMgungundlovu Health District, Pietermaritzburg, South Africa
*Corresponding author, email: juanjvanvuuren@icloud.com
Introduction: Non-communicable diseases, especially cardiovascular diseases (CVD), have become more prevalent across the
world, more so in developing countries. Novel methods in the management of CVD risks in patients with diabetes mellitus,
type 2 (DM2) requires constant attention and an ever-evolving approach. The role of magnesium supplementation in the
management of CVD has been described, but the relationship between serum magnesium (Mg) and the lipid subsets have
had conflicting results in different population groups.
Methods: A cross-sectional study was performed by collecting data on patients with DM2 from a specialised diabetes clinic at
Edendale Hospital, Pietermaritzburg, KwaZulu-Natal, South Africa, between July 1, 2015 and June 30, 2016. Lipid subsets (total
cholesterol [TC], high-density lipoprotein cholesterol [HDL], low-density lipoprotein cholesterol [LDL] and triglycerides [TG]), age,
sex and Mg were recorded for analysis.
Results: A total of 495 clinical data sheets were analysed. The majority of participants were female (73.45%) with a mean age of
56.97 years. A statistically significant, positive, linear relationship was found between Mg and TC (R = 0.11; p = 0.01) as well as Mg
and LDL R = 0.14; p = 0.001), but not between Mg and HDL (R = 0.02; p = 0.66) and Mg and TG (R = 0.01; p = 0.82).
Discussion: The results of this study are similar to findings by a group of researchers in China and differ when compared with
studies observing Caucasian patients. It is plausible that intrinsic ethnic differences in lipid metabolism and the various ways in
which magnesium requiring enzymatic processes are utilised may be responsible for the results found in the present study
population versus those found in Caucasian study participants in other countries. More research is required to determine the
effect of magnesium supplementation and CVD outcomes in the present study population.
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Introduction
Non-communicable diseases (NCD) have become more preva-
lent as part of the so-called epidemiological shift.1 More than
two-thirds of deaths globally in 2012 were attributed to NCD.2
Cardiovascular disease (CVD) accounted for 46% of these
deaths, with diabetes mellitus (DM) linked to another 1.5
million deaths. This burden is experienced by individuals in
developing countries at a high rate. The WHO estimates that
low- and middle-income countries carry 83% of the burden of
deaths due to NCDs. This makes it important to develop multifa-
ceted approaches when managing these modifiable conditions.
Serum lipid subsets (low density lipoprotein cholesterol [LDL],
high density lipoprotein cholesterol [HDL] and total cholesterol
[TC] as well as triglycerides [TG]) have been implicated in the
development of CVD. HDL shows an inverse relationship with
CVD, while LDL has been shown to increase the risk of CVD
and is a good predictor of CVD in patients with DM.3,4
A similar positive relationship exists between TG and CVD.5
Relationship between plasma magnesium (Mg) levels and lipid
profiles in patients with diabetes mellitus, type 2 (DM2)
remains controversial.
Numerous studies have shown a relationship between Mg and
the lipid subsets; however, the conclusions drawn from these
studies differ markedly. In 2012 Huang et al. studied a popu-
lation of individuals with DM2 to determine the correlation
between Mg and metabolic parameters. They found a positive
relationship between Mg and HDL and a negative correlation
between Mg and TG.6 Rasheed et al. found a significant relation-
ship between Mg and HDL and a negative relationship between
Mg and LDL and TC.7 In 2016 Cao et al. found a positive relation-
ship between Mg and all the lipid subsets.8 Mirmiran et al.,
however, found no relationship at all between Mg and the
lipid subsets.9 Data in the African context remain scarce.
A meta-analysis of studies conducted worldwide (and published
in English) in 2017 reported that magnesium supplementation in
individuals with DM2 has a positive effect on their CVD out-
comes.10 The effects of the magnesium supplementation are
likely multifactorial and the authors advised that larger RCTs
be conducted. It is not clear whether African populations have
been represented appropriately in the studies performed. This
is important as magnesium handling, in conjunction with
various other minerals such as calcium, differs between races
where, for example, individuals of African descent have been
found to excrete magnesium less readily than their Caucasian
counterparts.11 Lipid metabolism, too, differs depending on
race. African American women have been shown to have a
higher apoCIII level than Caucasian women, which affects the
way HDL is handled.12
With the differing relationships shown between Mg and the lipid
subsets it is important to understand the relationship experi-
enced by specific populations. This study hopes to add to the
body of knowledge and assist the clinician in the decision to
advise supplementation with magnesium.
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Methods
A cross-sectional study was performed by collecting data on
patients with DM2 from a specialised diabetes clinic at Edendale
Hospital, Pietermaritzburg, KwaZulu-Natal, South Africa,
between July 1, 2015 and June 30, 2016. Data were collected
by reviewing information recorded on the standardised clinic
tool used by this clinic.13 The use of the data was approved by
the University of KwaZulu-Natal Biomedical Research Ethics
Committee (BCA 194/15).
The following data were recorded for analysis:




Normal lipid subset values (in mmol/l) were assumed at values
below target value for patients with DM:14,15
. TC < 4.5
. LDL < 1.8
. HDL > 1 (in males); >1.2 (in females)
. TG < 1.7
Mg was measured using the Siemens Dimension clinical chem-
istry system (Siemens Healthcare Diagnostics Inc, Deerfield, IL,
USA), which utilises a photometric method, a modified
methylthymol blue (MTB) complexometric procedure. This is
the commonest method used worldwide, with an assay range
of 0.0–8.22mmol/l. The assigned coefficients are as follows: C0
−0.200 and C1 0.100. Tests were performed by the National
Health Laboratory Service.
The data were analysed using the SOFA Statistics software
(ver. 1.4.6) (http://www.sofastatistics.com/downloads.php) and
Microsoft Excel (Microsoft Corp, Redmond, WA, USA). Univariate
and multivariate analyses were performed. Results were deemed
statistically significant at a p-value of < 0.05.
Results
The study reviewed 495 clinical data sheets. Themean age of the
patients was 56.97 years (±SD 12.29 years). Male patients
totalled 126 (25.45%), female patients totalled 364 (73.54%)
and unrecorded sex totalled 5 (1.01%). The mean Mg was
0.78mmol/l (SD 0.12mmol/l).
Table 1: Multivariate analysis of the mean serum magnesium of, and its





TC 4.45 mmol/l 1.25 mmol/l 0.11 0.01
HDL 1.30 mmol/l 1.04 mmol/l 0.02 0.66
Males 1.18 mmol/l 0.33 mmol/l 0.05 0.58
Females 1.33 mmol/l 0.39 mmol/l 0.01 0.84
LDL 2.35 mmol/l 0.38 mmol/l 0.14 0.001
TG 1.70 mmol/l 0.99 mmol/l 0.01 0.82
Figures 1a and 1e demonstrate significant, linear, positive
relationships between Mg and TC and Mg and LDL, respectively.
Figures 1b-d, and 1f demonstrate the lack of significant
relationships.
Discussion
The epidemiological shift has seen a rise in the prevalence of
NCD across the world.1 New strategies need to be developed
to curb the effects of NCD on the lives of millions. A meta-
analysis published in 2017 suggested that magnesium sup-
plementation has a positive effect on the outcome of CVD in
patients with DM2.10 The relationship between Mg and the
lipid subsets differ from study to study, depending on the
population studied. Studies analysing data obtained from indi-
viduals of African and Asian descent yield different results
when compared with studies where the population consists
mainly of Caucasian individuals.16,17 It is therefore important
to understand the correlation between Mg and the lipid
subsets in the local population to sensitise the clinician to
the possible population-specific relationship. This study
aimed to do that.
The sample population consisted mainly of females (73.54%)
with a mean age of 56.97. The mean Mg level was 0.78 mmol/
l. A statistically significant, positive relationship was found
between Mg and TC (p = 0.01) as well as between Mg and LDL
(p = 0.001). These findings are comparable to those published
by Cao et al.8 There was no evidence of a relationship
between Mg and HDL (0.66) or TG (0.82).
Intrinsic ethnic differences in lipid metabolisms is well
known, with overweight Caucasian females having a higher
visceral fat mass (VFM) compared with overweight African
females.18 This is significant as visceral fat and subcutaneous
fat are metabolically different structures and respond to
nutrients in varied ways.19,20 Although data pertaining to
the differences in enzyme concentrations and their response
to Mg are scarce, this may be a potential explanation for the
findings of our study, compared with those of other research-
ers. Magnesium is an important rate-limiting factor in the
biosynthesis of cholesterol in humans, where Mg acts by con-
trolling the enzymatic activity of HMG CoA reductase (similar
to statins), lecithin cholesterol acyl transferase and desatur-
ase.21 At the correct cellular concentration Mg acts by inhi-
biting calcium channels, modulating various cellular
processes and hence CVD risk. If the cellular activity of
these enzymes differs significantly in visceral vs. subcu-
taneous adipocytes, the effect of Mg will differ from popu-
lation to population.
Dietary and lifestyle differences in different populations and the
resultant effect on both Mg and the lipid subsets must be con-
sidered. The epidemiological shift of NCD, the burden of obesity
affecting developing countries and ever-increasing rates of
metabolic syndrome in sub-Saharan Africa and Asia could be a
contributing factor in the differences observed.22,23
Many limitations have been identified. Being a cross-sectional
study no causal relationship can be established. Information
regarding body mass, co-morbidities (such as established
deranged lipid profiles), the use of lipid or Mg altering drugs
(such as statins), ethanol intake and daily dietary intake have
not been recorded. It is recommended that in future studies
these potentially confounding factors be considered.
The purpose of this study was to add to the body of knowledge
regarding the relationship between Mg and the lipid subsets, as
Relationship between magnesium and lipids in patients with diabetes mellitus 47
The page number in the footer is not for bibliographic referencingwww.tandfonline.com/oemd 20
well as to sensitise clinicians to the potential impact of mag-
nesium supplementation on lipids in patients with DM2.
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